Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, discusses the data from the Phase III IMvigor130 trial (NCT02807636) being presented at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. This study evaluated atezolizumab monotherapy and atezolizumab with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma.